The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
SOCIETY: AGA This session highlights the latest research on novel prediction models in IBD as well as the role of the fecal microbiome and imaging in IBD…
MONITORING IBD BY INTESTINAL ULTRASOUND DECREASES TIME TO TREATMENT CHANGE AND TIME TO REMISSION IN COMPARISON TO CONVENTIONAL MANAGEMENT: ANALYSIS OF PATIENTS WITH IBD ON MULTIPLE IBD THERAPIES